PERRONE, GIULIA
 Distribuzione geografica
Continente #
NA - Nord America 1.841
EU - Europa 1.194
AS - Asia 1.137
AF - Africa 113
SA - Sud America 66
Totale 4.351
Nazione #
US - Stati Uniti d'America 1.831
CN - Cina 352
SG - Singapore 308
GB - Regno Unito 297
VN - Vietnam 285
SE - Svezia 197
DE - Germania 156
IT - Italia 138
HK - Hong Kong 71
FR - Francia 65
RU - Federazione Russa 64
UA - Ucraina 62
IN - India 57
NL - Olanda 56
IE - Irlanda 45
BR - Brasile 43
TG - Togo 35
CH - Svizzera 30
ZA - Sudafrica 28
CI - Costa d'Avorio 26
FI - Finlandia 21
EE - Estonia 18
JP - Giappone 18
BG - Bulgaria 14
BE - Belgio 13
SC - Seychelles 12
AR - Argentina 11
JO - Giordania 10
KR - Corea 10
NG - Nigeria 9
CA - Canada 8
IR - Iran 8
CO - Colombia 5
TR - Turchia 5
LB - Libano 4
PL - Polonia 4
AT - Austria 3
EC - Ecuador 3
LT - Lituania 3
RO - Romania 3
BD - Bangladesh 2
CL - Cile 2
GR - Grecia 2
IL - Israele 2
MA - Marocco 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ES - Italia 1
HR - Croazia 1
ID - Indonesia 1
MX - Messico 1
PA - Panama 1
PK - Pakistan 1
PY - Paraguay 1
VE - Venezuela 1
Totale 4.351
Città #
Southend 268
Ashburn 240
Chandler 218
Singapore 205
Fairfield 183
Dong Ket 130
Woodbridge 106
Ann Arbor 83
Seattle 82
Wilmington 77
Houston 76
Cambridge 72
Beijing 71
Hong Kong 71
Princeton 59
Dublin 45
Santa Clara 45
Bologna 39
Jacksonville 39
Boardman 38
Lomé 35
Nanjing 35
New York 32
Hefei 30
Abidjan 26
Bern 26
Bremen 25
Westminster 25
Padova 24
Helsinki 20
Shenyang 19
Ho Chi Minh City 18
Los Angeles 18
Tokyo 18
Jinan 17
Berlin 14
Changsha 14
Frankfurt am Main 14
Sofia 14
Turin 14
Brussels 13
Hebei 13
Buffalo 12
Hanoi 12
Saint Petersburg 12
Redwood City 11
Amman 10
Seoul 10
Abeokuta 9
Mülheim 9
Nanchang 9
Falkenstein 7
Medford 7
San Diego 7
Verona 7
Jiaxing 6
Monmouth Junction 6
Norwalk 6
Tianjin 6
Washington 6
Zhengzhou 6
Brooklyn 5
Hangzhou 5
Mahé 5
Milan 5
Munich 5
Paris 5
São Paulo 5
Wuhan 5
Amsterdam 4
Ardabil 4
Dallas 4
Dearborn 4
Denver 4
Falls Church 4
Guangzhou 4
Lanzhou 4
Pune 4
Redmond 4
Redondo Beach 4
Roubaix 4
Shanghai 4
Andover 3
Bexley 3
Boston 3
Haikou 3
Haiphong 3
Johannesburg 3
Kuban 3
Leawood 3
London 3
Montreal 3
Olalla 3
Orem 3
Portsmouth 3
Sacramento 3
San Francisco 3
Taizhou 3
The Dalles 3
Warsaw 3
Totale 2.915
Nome #
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. 311
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 283
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 231
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 206
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 194
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 181
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 179
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 179
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 178
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 168
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 165
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 164
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 162
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 160
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 156
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 150
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 150
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 148
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 146
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 146
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 140
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 138
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 137
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 133
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 129
Proteasome inhibitors: Bortezomib in multiple myeloma 75
Totale 4.409
Categoria #
all - tutte 11.547
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.547


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021357 0 0 0 0 0 14 12 25 29 25 46 206
2021/2022606 96 15 32 41 51 34 7 30 20 65 107 108
2022/2023816 88 142 34 130 42 69 24 34 112 25 54 62
2023/2024207 10 32 14 20 25 65 11 5 2 8 6 9
2024/2025530 10 57 41 39 76 34 45 31 3 76 7 111
2025/2026651 132 91 101 87 168 72 0 0 0 0 0 0
Totale 4.409